DYRK1A and colonic neoplasm: As shown in this study, DYRK1A KO leads to inhibition of colony formation in vitro (Fig. 2a) as well as inhibition of tumor formation in vivo in preclinical models of breast and colon cancers (Fig. 2c–h).